Shots:
Vertex gets the non-exclusive clinical & commercial rights to use MaxCyte’s Flow Electroporation technology & ExPERT platform to develop exa-cel, CTX001 for hemoglobinopathies while MaxCyte will receive platform licensing fees & program-related revenue
ExPERT platform can be used across the high-growth cell therapy sector from discovery and development & to commercialization of cell-based therapies. It has been developed to support the quickly growing cell therapy business
Exa-cel is an ex vivo CRISPR gene-edited cell therapy & is currently being studied in the P-II/III study. The therapy is indicated for the treatment of TDT or SCD characterized by recurrent vaso-occlusive crises
Ref: Globenewswire | Image: MaxCyte
